116 related articles for article (PubMed ID: 30995172)
1. Immunotherapy in Non-Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence.
Passaro A; Spitaleri G; Gyawali B; de Marinis F
J Clin Oncol; 2019 Aug; 37(22):1863-1867. PubMed ID: 30995172
[No Abstract] [Full Text] [Related]
2. Immunotherapy in non-small cell lung cancer: advancements and challenges.
Zhou F; Zhou CC
Chin Med J (Engl); 2021 Feb; 134(10):1135-1137. PubMed ID: 33595975
[No Abstract] [Full Text] [Related]
3. [Immunotherapy advances for lung cancer combined with chronic obstructive pulmonary disease].
Tian H; Chao YC; Hu J; Song YL
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):70-74. PubMed ID: 38062699
[TBL] [Abstract][Full Text] [Related]
4. Perspectives on imaging and immunotherapy: a review series.
de Vries EG; Schwartz LH
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35710295
[No Abstract] [Full Text] [Related]
5. First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F; Mazzaschi G; Barbieri F; Passiglia F; Mazzoni F; Berardi R; Proto C; Cecere FL; Pilotto S; Scotti V; Rossi S; Del Conte A; Vita E; Bennati C; Ardizzoni A; Cerea G; Migliorino MR; Sala E; Camerini A; Bearz A; De Carlo E; Zanelli F; Guaitoli G; Garassino MC; Ciccone LP; Sartori G; Toschi L; Dall'Olio FG; Landi L; Pizzutilo EG; Bartoli G; Baldessari C; Novello S; Bria E; Cortinovis DL; Rossi G; Rossi A; Banna GL; Camisa R; Di Maio M; Tiseo M
Eur J Cancer; 2020 May; 130():155-167. PubMed ID: 32220780
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS; Giaccone G; de Marinis F; Reinmuth N; Vergnenegre A; Barrios CH; Morise M; Felip E; Andric Z; Geater S; Özgüroğlu M; Zou W; Sandler A; Enquist I; Komatsubara K; Deng Y; Kuriki H; Wen X; McCleland M; Mocci S; Jassem J; Spigel DR
N Engl J Med; 2020 Oct; 383(14):1328-1339. PubMed ID: 32997907
[TBL] [Abstract][Full Text] [Related]
7. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial.
Middleton G; Brock K; Savage J; Mant R; Summers Y; Connibear J; Shah R; Ottensmeier C; Shaw P; Lee SM; Popat S; Barrie C; Barone G; Billingham L
Lancet Respir Med; 2020 Sep; 8(9):895-904. PubMed ID: 32199466
[TBL] [Abstract][Full Text] [Related]
10. Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status.
Alessi JV; Ricciuti B; Jiménez-Aguilar E; Hong F; Wei Z; Nishino M; Plodkowski AJ; Sawan P; Luo J; Rizvi H; Carter BW; Heymach JV; Altan M; Hellmann M; Awad M
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753547
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
Goldberg SB; Schalper KA; Gettinger SN; Mahajan A; Herbst RS; Chiang AC; Lilenbaum R; Wilson FH; Omay SB; Yu JB; Jilaveanu L; Tran T; Pavlik K; Rowen E; Gerrish H; Komlo A; Gupta R; Wyatt H; Ribeiro M; Kluger Y; Zhou G; Wei W; Chiang VL; Kluger HM
Lancet Oncol; 2020 May; 21(5):655-663. PubMed ID: 32251621
[TBL] [Abstract][Full Text] [Related]
12. Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.
Friedlaender A; Banna GL; Buffoni L; Addeo A
Curr Oncol Rep; 2019 Nov; 21(12):107. PubMed ID: 31768759
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study.
Garon EB; Hellmann MD; Rizvi NA; Carcereny E; Leighl NB; Ahn MJ; Eder JP; Balmanoukian AS; Aggarwal C; Horn L; Patnaik A; Gubens M; Ramalingam SS; Felip E; Goldman JW; Scalzo C; Jensen E; Kush DA; Hui R
J Clin Oncol; 2019 Oct; 37(28):2518-2527. PubMed ID: 31154919
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data and Evidence in Lung Cancer: A Review of Recent Developments.
Kokkotou E; Anagnostakis M; Evangelou G; Syrigos NK; Gkiozos I
Cancers (Basel); 2024 Apr; 16(7):. PubMed ID: 38611092
[TBL] [Abstract][Full Text] [Related]
15. The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy.
Gómez Rueda A; Taus Á; Álvarez Álvarez R; Bernabé-Caro R; Chara L; López-Brea M; Vilà L; Sala González MÁ; Del Barrio Díaz Aldagalán A; Esteban Herrera B; López Castro R; Álvarez Cabellos R; Doménech M; Falagan S; Moreno Vega A; Aguado C; Barba A; Delgado Ureña MT; Isla D; Bellido Hernández L; Fírvida Pérez JL; Juan-Vidal Ó; Massutí B; Mielgo-Rubio X; Ortega AL; Catot S; Dómine M; Escoín-Pérez C; García Navalón F; Gil-Bazo I; Muñoz S; Rodríguez-Abreu D; Villatoro Roldán RM; Alonso-Jáudenes Curbera G; León-Mateos L; Padilla A; Paredes Lario A; Sánchez-Torres JM; Garrido P;
Clin Transl Oncol; 2024 Jul; 26(7):1779-1789. PubMed ID: 38512450
[TBL] [Abstract][Full Text] [Related]
16. Utility of contrast-enhanced MRI radiomics features combined with clinical indicators for predicting induction chemotherapy response in primary central nervous system lymphoma.
Wang X; Zhao L; Wang S; Zhao X; Chen L; Sun X; Liu Y; Liu J; Sun S
J Neurooncol; 2024 Feb; 166(3):451-460. PubMed ID: 38308802
[TBL] [Abstract][Full Text] [Related]
17. The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer.
Ducceschi M; Polignano M; Bini M; Lopez S; Conca E; Tamborini E; Perrone F; Carlo Stella G; Petrella MC; Carciotto R; Artioli G; Maffeis V; Sartor L; Raspagliesi F; Mantiero M
J Clin Med; 2023 Aug; 12(17):. PubMed ID: 37685607
[TBL] [Abstract][Full Text] [Related]
18. Real-World Outcomes of Stage IV NSCLC with PD-L1 ≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy.
Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2023 May; 30(6):5299-5308. PubMed ID: 37366885
[TBL] [Abstract][Full Text] [Related]
19. Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.
Meyers DE; Pasternak M; Dolter S; Grosjean HAI; Lim CA; Stukalin I; Goutam S; Navani V; Heng DYC; Cheung WY; Morris DG; Pabani A
JTO Clin Res Rep; 2023 Apr; 4(4):100482. PubMed ID: 37090101
[TBL] [Abstract][Full Text] [Related]
20. New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors.
Lin X; Chen X; Long X; Zeng C; Zhang Z; Fang W; Xu P
Respir Res; 2023 Feb; 24(1):64. PubMed ID: 36849947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
